Welcome to our dedicated page for Bausch + Lomb Corporation SEC filings (Ticker: BLCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Scanning Bausch + Lomb’s disclosures often means sorting through pages of ophthalmic product data, FDA commentary and intangible-asset valuations. If you’re trying to discover how a new contact-lens material shapes margins or when a recall dents revenue, the details sit deep inside the 10-K and rolling 8-K updates. That complexity fuels searches like “Where can I find Bausch + Lomb’s quarterly earnings reports?” and “What do Bausch + Lomb executives disclose in Form 4?”. Stock Titan’s AI reads every footnote and delivers Bausch + Lomb SEC filings explained simply.
Our platform streams each filing the moment it hits EDGAR—10-Q, 10-K, 8-K, Section 16, S-1 and more—and converts them into plain-language insights. Want the highlights from a “Bausch + Lomb quarterly earnings report 10-Q filing”? We tag segment revenue and inventory shifts instantly. Need “Bausch + Lomb insider trading Form 4 transactions” or real-time alerts for “Bausch + Lomb executive stock transactions Form 4”? They arrive with context. Even dense proxies become digestible: “Bausch + Lomb proxy statement executive compensation” is broken into clear pay tables by our AI.
- AI-powered summaries translate complex notes into plain language
- Real-time alerts for every Form 4 and 8-K
- Comprehensive access to all Bausch + Lomb filings
Here, “understanding Bausch + Lomb SEC documents with AI” is routine. Jump to “Bausch + Lomb 8-K material events explained,” review a “Bausch + Lomb annual report 10-K simplified” snapshot, or export numbers for your “Bausch + Lomb earnings report filing analysis.” Investors track product-line growth, surgeons follow new device approvals, and analysts watch “Bausch + Lomb Form 4 insider transactions real-time” for sentiment shifts—all without decoding legal jargon.
Bausch + Lomb reported Q3 2025 results with revenue of $1,281 million, up from $1,196 million a year ago, and operating income of $95 million versus $43 million. The quarter showed a net loss attributable to the company of $28 million (–$0.08 per share) compared to net income of $4 million ($0.01) last year, reflecting higher interest expense and other below‑the‑line items despite stronger operations.
For the first nine months, revenue reached $3,696 million (from $3,511 million) and the company recorded a net loss of $302 million (from $314 million). Cash from operations was $147 million, while investing cash outflows of $267 million included higher capex. Long‑term debt stood at $4,922 million and cash and equivalents at $310 million as of September 30, 2025. Bausch Health owned about 88% of BLCO as of October 22, 2025, and the planned separation remains subject to conditions. Shares outstanding were 354,189,784 as of October 22, 2025.
Bausch + Lomb Corporation furnished an 8-K announcing results of operations for the quarter ended September 30, 2025. The detailed financial information is provided in a press release attached as Exhibit 99.1.
The Item 2.02 information is being furnished and is not deemed filed under the Exchange Act, and it is not incorporated by reference into Securities Act filings. The company’s common shares trade as BLCO on the NYSE and Toronto Stock Exchange.
FAQ
What is the current stock price of Bausch + Lomb Corporation (BLCO)?
What is the market cap of Bausch + Lomb Corporation (BLCO)?
